These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 15270652)

  • 1. Progress toward development of an inhalation vaccine against botulinum toxin.
    Park JB; Simpson LL
    Expert Rev Vaccines; 2004 Aug; 3(4):477-87. PubMed ID: 15270652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulism and vaccines for its prevention.
    Smith LA
    Vaccine; 2009 Nov; 27 Suppl 4():D33-9. PubMed ID: 19837283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New targets in the search for preventive and therapeutic agents for botulism.
    Anniballi F; Lonati D; Fiore A; Auricchio B; De Medici D; Locatelli CA
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1075-86. PubMed ID: 25089560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines against botulism.
    Karalewitz AP; Barbieri JT
    Curr Opin Microbiol; 2012 Jun; 15(3):317-24. PubMed ID: 22694934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of investigational recombinant botulinum vaccine, rBV A/B, in volunteers with pre-existing botulinum toxoid immunity.
    Khouri JM; Motter RN; Arnon SS
    Vaccine; 2018 Apr; 36(15):2041-2048. PubMed ID: 29475762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum neurotoxin vaccines: Past history and recent developments.
    Rusnak JM; Smith LA
    Hum Vaccin; 2009 Dec; 5(12):794-805. PubMed ID: 19684478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
    Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
    Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
    Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunization of broiler chickens against type C botulism.
    Dohms JE; Allen PH; Cloud SS
    Avian Dis; 1982; 26(2):340-5. PubMed ID: 7049149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
    Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(42):1454-5. PubMed ID: 22031218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
    Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment.
    Foynes S; Holley JL; Garmory HS; Titball RW; Fairweather NF
    Vaccine; 2003 Mar; 21(11-12):1052-9. PubMed ID: 12559779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulism, where are we now?
    Zhang JC; Sun L; Nie QH
    Clin Toxicol (Phila); 2010 Nov; 48(9):867-79. PubMed ID: 21171845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What next for botulism vaccine development?
    Webb RP; Smith LA
    Expert Rev Vaccines; 2013 May; 12(5):481-92. PubMed ID: 23659297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A.
    Yu YZ; Zhang SM; Sun ZW; Wang S; Yu WY
    Vaccine; 2007 Dec; 25(52):8843-50. PubMed ID: 18022294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.
    Yu YZ; Li N; Zhu HQ; Wang RL; Du Y; Wang S; Yu WY; Sun ZW
    Vaccine; 2009 May; 27(21):2816-22. PubMed ID: 19428892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Clostridium botulinum types C and D toxoid vaccination in Danish cows.
    Krüger M; Skau M; Shehata AA; Schrödl W
    Anaerobe; 2013 Oct; 23():97-101. PubMed ID: 23831724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Observations on the effect of the diluent used for diluting challenge toxin in the Clostridium botulinum potency test.
    Sawtell JA; Ream AJ
    Biologicals; 1995 Sep; 23(3):249-51. PubMed ID: 8527126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.